Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study
Open accessThe DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Abstract
In recent years the use of immunomodulating therapy to treat various cancers has been on the rise. Three checkpoint inhibitors have been approved by the Food and Drug Administration (ipilimumab, pembrolizumab and nivolumab). The use of these drugs comes with serious adverse events related to excessive immune activation, collectively known as immune-related adverse events (irAEs). We conducted a system-based review of 139 case reports/case series that have described these adverse events between January 2016 and April 2018, found in the PubMed database. There was a broad spectrum of presentations, doses and checkpoint inhibitors used. The most common check point inhibitor observed in our literature review was nivolumab. The most common adverse effects encountered were colitis (14/139), hepatitis (11/139), adrenocorticotropic hormone insufficiency (12/139), hypothyroidism (7/139), type 1 diabetes (22/139), acute kidney injury (16/139) and myocarditis (10/139). The treatment most commonly consisted of cessation of the immune checkpoint inhibitor, initiation of steroids and supportive therapy. This approach provided a complete resolution in a majority of cases; however, there were many that developed long-term adverse events with deaths reported in a few cases. The endocrine system was the mostly commonly affected with the development of type 1 diabetes mellitus or diabetic ketoacidosis being the most frequently reported adverse events. While immunomodulating therapy is a significant advance in the management of various malignancies, it is capable of serious adverse effects. Because the majority of the cases developed pancreatic dysfunction within five cycles of therapy, in addition to the evaluation of other systems, pancreatic function should be closely monitored to minimize adverse impact on patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“overactivation of the immune system to boost antitumor immunity can act as a double-edged sword, leading to the development of irAEs that can range from mild rash to severe colitis to life-threatening myocarditis (114, 115).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“30-60% of patients experience irAEs of any grade”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
Experimental — accuracy not yet measuredIn the citing paper
“approximately 10-20% experience more severe grade 3 or 4 irAEs”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
In the citing paper
“Newly developed autoimmune disease, such as type I diabetes in patients with no prior history of the disease, following checkpoint therapy has also been reported to occur”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 2×
“This over-activation can potentially affect multiple organ systems including the gastrointestinal tract, kidneys, nervous system, liver, eyes, skin, pancreas and endocrine system [8-12].”
BackgroundThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 4×
“This over-activation can potentially affect multiple organ systems including the gastrointestinal tract, kidneys, nervous system, liver, eyes, skin, pancreas and endocrine system [8-12].”
BackgroundInfluentialFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308 · cited 4×
“The cases are illustrated in Table 3 below [95-102].”
BackgroundInfluentialThe Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J. I., Salama, A. D., Chitnis, T., Smith, R. N., Yagita, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 814 · cited 1×
“This process is regulated by stimulatory, co-stimulatory, and inhibitory (checkpoint) signals [4-6].”
BackgroundBertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704 · cited 1×
“Many of the conditions can be life-threatening calling for discontinuation of treatment, long-term corticosteroids and at times anti-tumor necrosis factor therapy [13].”
BackgroundOkazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., et al. (2003) · Nature Medicine · doi:10.1038/nm955 · Cited by 689 · cited 1×
“Another study published in Nature Medicine reported that mice deficient in the PD-1 immuno-inhibitory co-receptor develop autoimmune dilated cardiomyopathy with production of high titer autoantibodies against a heart specific protein [115].”
BackgroundImmune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 515 · cited 4×
“The patients who received FDA-approved checkpoint inhibitors such as ipilimumab, pembrolizumab and nivolumab were considered whether they received the treatment in a clinical trial or as part of standard of care.”
BackgroundInfluentialCardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511 · cited 3×
“The cases are illustrated in Table 3 below [95-102].”
Background
Cited by
Items 101–180 of 180
Coelho, J. Q., Romão, R., Sousa, M. J., Azevedo, S. X., Fidalgo, P., & Araújo, A. (2024) · Current Oncology · doi:10.3390/curroncol31020083 · Cited by 7
“Collectively recognized as immune-related adverse events (irAEs) and with the potential to affect any organ or system, these are related to the increased immune activation [7].”
BackgroundIs it metastatic melanoma or is it sarcoidosis? Non-caseating granulomas due to pembrolizumab
Chahin, M., Stack, A., Siddiqi, A. M., & Shaikh, M. E. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-240701 · Cited by 7
Crosby, B. J., López, P., Galvao, D. A., Newton, R. U., Taaffe, D. R., Meniawy, T. M., Warburton, L., Khattak, M. A., Gray, E. S., & Singh, F. (2021) · Integrative Cancer Therapies · doi:10.1177/15347354211040757 · Cited by 8
Dang, T., Macwan, S., & Dasanu, C. A. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220976797 · Cited by 7
Nivolumab-associated cutaneous T-cell lymphoma
Marks, J. A., Parker, D. C., Garrot, L. C., & Lechowicz, M. J. (2021) · JAAD Case Reports · doi:10.1016/j.jdcr.2020.12.033 · Cited by 7
“DISCUSSION Pharmacologic immunomodulators are becoming staples in managing solid and liquid malignancies.(1) To our knowledge, this article is the first to describe the development of CTCL associated with nivolumab treatment for advanced RCC.”
BackgroundInfluentialAngioedema late in the course of adjuvant nivolumab therapy for melanoma
Ratra, A., & Dasanu, C. A. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219881181 · Cited by 7
“melanoma, small cell and non-small cell lung cancer, hepatocellular carcinoma, advanced renal carcinoma and urothelial cancer.(9,10) Cutaneous side effects documented in clinical trials and real world experiences include immune-mediated rash and pruritus.”
BackgroundClinical and Advanced MRI Techniques for Detection of Checkpoint Inhibitor Associated Myocarditis
Arbune, A., Soufer, A., & Baldassarre, L. A. (2020) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-019-9521-5 · Cited by 6
Almutairi, A. R., Slack, M. K., Erstad, B. L., McBride, A., & Abraham, I. L. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098621991279 · Cited by 7
Bross, S. P., Mongelluzzo, G. J., Conger, A. R., Patel, M. A., Vadakara, J., Grant, M., & Gatson, N. T. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.04.177 · Cited by 6
Singh, B., Kaur, P., & Maroules, M. (2021) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709621992207 · Cited by 6
“6 For the evaluation of HPD in our patient, we used Lo Russo and colleagues7 recommended criteria (diagnosis of HPD requires at least 3 of the following criteria): (1) time-to-treatment failure, which is defined as the time between the start and the discontinuation of immunotherapy of less than 2 months; (2) a ≥50% in…”
MethodCase series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy
Gatson, N. T., Makary, M., Bross, S. P., Vadakara, J., Maiers, T., Mongelluzzo, G. J., Leese, E. N., Brimley, C., Fonkem, E., Mahadevan, A., et al. (2020) · Neuro-Oncology Practice · doi:10.1093/nop/npaa079 · Cited by 5
The role of PET/CT in thyroid autoimmune diseases
CALIFARETTI, E., Dall’Armellina, S., Rovera, G., Finessi, M., & Deandreis, D. (2022) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.22.03464-1 · Cited by 5
Immunotherapy utilization in stage IIIA melanoma: less may be more
Frey, A. E., Kerekes, D. M., Khan, S. A., Tran, T. T. T., Kluger, H. M., Clune, J. E., Ariyan, S., Sznol, M., Ishizuka, J. J., & Olino, K. L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1336441 · Cited by 6
Kamta, J., Magruder, B., & Hymel, L. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220970266 · Cited by 4
“For example, cardiovascular toxicities such as myocarditis and pericardial disease are some of the least common irAEs, but most likely to be fatal.(6,7) Further complicating matters, rare cases of irAEs developing over a year after the last ICI treatment have been reported, and NCCN guidelines currently recommend to m…”
BackgroundWalker, A., Chan, A., Labra, C. C., de Lemos, M. L., Geirnaert, M., Marí, A. A., Aras‐Atik, E., Borlagdan, J., Crespo, A., Danilak, M., et al. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221090199 · Cited by 4
“23,24 Early identi fi cation of potential irAEs and patient counselling are essential in ensuring patient safety and are areas where oncology pharmacists can provide signi fi cant bene fi t.”
Background“Getting the Dose Right”—Revisiting the Topic With Focus on Biologic Agents
Mould, D. R., & Upton, R. N. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3285 · Cited by 4
“19 The ICI MAbs have associated adverse events that are immune related, with high frequencies of 10–40% for grade 3/4, and 0.3–1.2% for fatal (grade 5) 20 and are often higher incidence with earlier onset in combination therapy.”
InfluentialPrimary Lung Adenocarcinoma Presenting as Cardiac Tamponade in a Pregnant Woman
Bigeh, A., Trutter, L., & Gulati, M. (2020) · JACC Case Reports · doi:10.1016/j.jaccas.2019.11.067 · Cited by 4
“Patients using immune checkpoint inhibitor chemotherapy agents primarily develop side effects related to excessive immune activation with varying levels of cardiotoxicity (6).”
BackgroundSeyfoori, A., Barough, M. S., Amereh, M., Jush, B. K., Lum, J. J., & Akbari, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.028 · Cited by 5
Gobbi, M. F., Eduardo, F. D. P., Bezinelli, L. M., de Carvalho, D. L. C., do Vale, S. K. M., & Côrrea, L. (2021) · Special Care in Dentistry · doi:10.1111/scd.12660 · Cited by 4
Escudero, O. G. (2024) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2023.11.001 · Cited by 4
Abordaje de la diarrea crónica en el adulto: Revisión de la literatura
Gomez-Escudero, O., & Remes-Troche, J. M. (2021) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2021.02.002 · Cited by 7
Wei, Z., Kou, Z., Luo, Y. H., & Cheng, Y. (2025) · Medicine · doi:10.1097/md.0000000000041578 · Cited by 3
Barker, S. B., & Adewuyi, A. (2025) · Cureus · doi:10.7759/cureus.84121 · Cited by 3
Severe autoimmune-mediated thrombocytopenia in an elderly woman
WEI, M., Ding, H., & WANG, Y. (2022) · The National Medical Journal of India · doi:10.25259/nmji_196_20 · Cited by 3
SEVERE MULTIFOCAL PLACOID CHORIORETINITIS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR THERAPY
Yu, J. J., Everett, L. A., Sassalos, T. M., & Johnson, M. W. (2023) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000001413 · Cited by 3
Du, Y. J., Fu, R., Levinsky, J. T., Kamalraj, P., Chan, K., Parmar, A., Eskander, A. E., & Smoragiewicz, M. (2023) · Current Oncology · doi:10.3390/curroncol30100645 · Cited by 3
“Pembrolizumab is now available for first-line treatment of R/M HNSCC, and the use of nivolumab will likely decrease [13,14].”
BackgroundRiveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Plazas, J. G., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2024.10250/2024 · Cited by 3
Riveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Gallego-Plazas, J., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2023.10.003 · Cited by 4
INTRACELLULAR MECHANISMS OF TUMOR CELL IMMUNORESISTANCE
Hermanowicz, J. M., Sieklucka, B., Nosek, K., & Pawlak, D. (2020) · Acta Biochimica Polonica · doi:10.18388/abp.2020_2878 · Cited by 6
“This upregulation can potentially affect one or more organs, leading to pneumonitis, hypothyroidism, hepatitis, colitis, as well as more general adverse events, such as fatigue, diarrhea, and rash (Ai & Curran, 2015; Turnis et al., 2015; Bajwa et al., 2019; Da1 et al., 2020).”
BackgroundImplantable and long-lasting drug delivery systems for cancer treatment
Pacheco, C., Baião, A., Sousa, F., & Sarmento, B. F. C. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821749-8.00011-2 · Cited by 4
Constantinescu, C. S., Paşca, S., Zimța, A., Tat, T., Rus, I., Teodorescu, P., Iluta, S., Tănase, A., Coliţă, A., Sigurjónsson, Ó. E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092903 · Cited by 3
“immune checkpoint inhibitors (anti-CTLA4 and anti-PD1) T-cells and APCs, or T-cells and malignant cells malignancies with high genomic instability â physiological immunosuppression is stopped throughout the whole body â immune system begins to react more to the self-antigens (autoimmunity) [48,49]”
BackgroundKnoedler, L., Huelsboemer, L. F., Hollmann, K., Alfertshofer, M. G., Herfeld, K., Hosseini, H. C., Boroumand, S., Stögner, V. A., Safi, A., Perl, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1276306 · Cited by 4
PD-L1 Detection on Circulating Melanoma Cells
Po, J. W., Ma, Y., Balakrishnar, B., Brungs, D., Azimi, F., Cooper, A. J., Saricilar, E. C., Murthy, V., SOUZA, P. D., & Becker, T. M. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1205-7_17 · Cited by 3
Tirnanić, T., Tiodorović, D., Vidović, N., Balić, M., Petrov, N., Sekulović, L. K., & Mijušković, Ž. P. (2023) · Acta Dermatovenerologica Alpina Pannonica et Adriatica · doi:10.15570/actaapa.2023.22 · Cited by 4
“These adverse events commonly affect various organs, including the skin, gastrointestinal organs, endocrine glands, and lungs (2, 3).”
BackgroundManagement of multiorgan failure caused by immune checkpoint inhibitor toxicity
Verma, T., Jawadi, A., & Ahmed, S. (2025) · BMJ Case Reports · doi:10.1136/bcr-2024-262209 · Cited by 2
“8 Infrequently, these adverse effects of ICIs can even present as severe complications, such as organ failure, which can ultimately be fatal, and are collectively termed immune-related adverse events (irAEs).”
InfluentialSivaprakasam, T., Nitchaikulvatana, P., Gedallovich, J., Shah, J. C., & Baker, M. C. (2025) · BMC Rheumatology · doi:10.1186/s41927-025-00548-1 · Cited by 2
“Immune checkpoint inhibitors (ICIs) are a group of immunomodulatory therapies that have greatly revolutionized the treatment of various cancers by harnessing the body’s immune system to aid in cancer cell destruction [1, 2].”
Das, U. N. (2020) · Springer eBooks · doi:10.1007/978-1-0716-0741-1_6 · Cited by 2
Immune Checkpoint Inhibitors and Perioperative Considerations
Robinson, A., & Wolfe, R. C. (2020) · Journal of PeriAnesthesia Nursing · doi:10.1016/j.jopan.2020.08.007 · Cited by 2
Cardiovascular Vulnerability to COVID-19 in Cancer SurvivorsPreprint
Zordoky, B. N. M. (2020) · Preprints.org · doi:10.20944/preprints202004.0128.v1 · Cited by 2
“inhibitors have also been associated with increased risk of myocarditis [63].”
BackgroundTauseef, A., Zafar, M., Siddiqui, S. A. H., Dufani, J., DeVrieze, B., Mirza, M., Thirumalareddy, J., Sood, A., & Mirza, M. M. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1438_23 · Cited by 3
Pancreatic adverse events induced by immune checkpoint inhibitors: a real-world observational study
Zhan, M., Long, Q., He, J., Huang, L., Liu, R., Wu, B., & Xu, T. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2493783 · Cited by 1
Shi, Z., Sun, Z., Zhang, D., & Zhao, L. (2025) · Discover Oncology · doi:10.1007/s12672-025-02607-y · Cited by 2
“For example, it has been found that while lifting immunosuppression, T cells activated by ICIs can also induce autoimmune associated inflammation through pro-inflammatory cytokines, which is considered to be the immunological basis of many irAEs [4].”
Case Report: Pembrolizumab associated lichen planus in early stage triple negative breast cancer
Büyükahısha, Ö., Özçelik, A., Bayçelebi, D., Cakir, A., & Çetin, B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1726097 · Cited by 1
Zhan, M., Long, Q., Liu, R., Huang, L., Wu, B., Xu, T., & He, J. I. (2026) · Clinical Cardiology · doi:10.1002/clc.70312 · Cited by 2
“So common toxicities are well described in the literature, and their management protocols have been established [4, 5].”
Fernandes, N. L., Sodavarapu, S., Nedopil, S., Mohapatra, N., & Vyas, D. (2020) · Cureus · doi:10.7759/cureus.8786 · Cited by 1
“A recent review suggested that additional gastrointestinal effects, such as vanishing bile duct syndrome and acute liver failure, may also be related to pembrolizumab treatment [14].”
BackgroundXavier, P., & Oliveira, J. G. (2021) · Open Journal of Nephrology · doi:10.4236/ojneph.2021.111006 · Cited by 1
Arko, R., Boc, N., & Boc, M. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2021.100026 · Cited by 1
Severe Cerebellar Syndrome Linked With Durvalumab
Tang, C. G., & Rakočević, G. (2020) · Journal of Neurology Research · doi:10.14740/jnr571 · Cited by 1
“This approach provided a complete resolution in a majority of cases; however, many patients developed irreversible adverse events including deaths reported in a few cases [8].”
Simões, J. L. B., Braga, G. D. C., Coiado, J. V., Scaramussa, A. B., Rodrigues, A. P. B., & Bagatini, M. D. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116388 · Cited by 1
NIVOLUMAB-INDUCED DIABETIC KETOACIDOSIS
Burgei, J. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.740 · Cited by 1
The Use of PET in Evaluating the Efficacy of Immunotherapy in Oncology
Nguyen, J., Aparici, C. M., Nayak, S. M., & Franc, B. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-81261-4_20 · Cited by 1
Cardiotoxicity from Immune Checkpoint Inhibitors: Myocarditis
Onderko, L. L., Bennett, E., & Francis, S. A. (2022) · Journal of Maine Medical Center · doi:10.46804/2641-2225.1104 · Cited by 1
Taylor, E. M., Koss, B. S., Washam, C. L., Shalin, S. C., Barreto, J. C., Graw, S., Byrum, S. D., Mackintosh, S. G., Edmondson, R. D., & Tackett, A. J. (2020) · Research Square · doi:10.21203/rs.3.rs-69890/v1 · Cited by 2
“These adverse effects linked to ICIs include colitis, pneumonitis, myocarditis and neurotoxic effects and can be su ciently severe to contribute to death (3).”
BackgroundOne man’s trash-another man’s treasure: fecal transplantation
Gupta, N., & Hanauer, S. B. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.06.05
“Although the immune system has the inherent ability to distinguish self from non-self and thus typically mount an attack on the non-self-cancer cells; over-activation of the immune response can lead to serious adverse events collectively called immune-related adverse events (irAEs) (3).”
Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises
Butt, S.-U.-R., Khan, M. S. I., Murias, C., Gonzalez-Exposito, M. R., Arkenau, H., & Patrikidou, A. (2019) · annals of urologic oncology · doi:10.32948/auo.2019.09.04
“Recently long‐ term follow up of patients who received checkpoint inhibitors also reported cardiac toxicity and death [36].”
BackgroundToxicity and pharmacokinetic biomarkers for personalized non-small cell lung cancer treatment
Svedberg, A. (2020) · Linköping University medical dissertations · doi:10.3384/diss.diva-163123
Thermothérapies guidées par imagerie pour le traitement des cancers
Jeanjean, P. (2019) · theses.fr (ABES) · doi:10.70675/59cc33b0z3e2ez4748z92ddz5b0eba60b8c9
Inmunoterapia en Cáncer Vesical. Presente y Futuro
del Val, M. P., Martínez-Rodríguez, R. H., & Amón-Sesmero, J. H. (2021) · Revista Mexicana de Urología · doi:10.48193/rmu.v80i6.651
Immuntherapien - Hoffnungsträger in der Therapie des Zervixkarzinoms
Gantner, L. F. (2021) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-021-8694-7
Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer
Singh, B., Kaur, P., Gupta, S. K., Guragai, N., & Maroules, M. (2021) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096211035603
Therapeutic Intervention in Skin Cancer: Future Prospects
Srivastava, R. (2021) · Springer eBooks · doi:10.1007/978-981-16-0364-8_2
Financing Agreement for Credit 4690-MV Conformed
Musiime, S. B. (2010)
Gu, L., Li, S., Du, N., Yao, Q., Fu, X., Lou, Y., Wang, M., Mao, F., Mao, D., Khadaroo, P. A., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-17064/v1 · Cited by 1
(2021) · International Journal on Oncology and Radiotherapy · doi:10.51626/ijor.2021.02.00007
Targeted therapy for metastatic colorectal cancer: what do we currently have in clinical practice?
Morgado, S., da Silva, M. S. G. O., Fonseca, O., Roque, F., & Morgado, M. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00915-9
“The immune checkpoint inhibitors (pembrolizumab, nivolumab and ipilimumab) are associated with significant adverse events related to the immune system, which can affect any organ or system of the body, the most frequent being gastrointestinal tract, endocrine glands, skin, and liver [68].”
BackgroundPage, D., Pucilowska, J., Chun, B., Kim, I., Sanchez, K., Moxon, N., Mellinger, S. L., Wu, Y., Koguchi, Y., Conrad, V. K., et al. (2023) · immuneACCESS · doi:10.21417/dbp2023npj
Acquired angioedema late in the course of nivolumab treatment
Habibi, S., Patel, N., Plaxe, S. C., & Dasanu, C. A. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231170555
Combinations with Cold Atmospheric Pressure Plasma Therapy
(2023) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781837672226-00274
Gomez-Escudero, O. (2024) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2023.11.001 · Cited by 1
Chung, Y. H., & Steinmetz, N. F. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4402-7_2
The Immunoradiotherapy in Nasopharyngeal Carcinoma
Miao, J., Xiang, C., & Liu, C. (2025) · Springer eBooks · doi:10.1007/978-981-96-3659-4_6
CDKL3 Targets ATG5 to Exacerbate the Progression of Malignant Melanoma
Chen, Q., Yu, W., Gu, Y., Cao, S., Xie, X., & Wu, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.70002
“Unfortunately, these inhibitors have a propensity for generating systemic side effects, such as type 1 diabetes, hypothyroidism, acute kidney injury and cutaneous toxicities [26 – 28].”
The Impact of Fecal Diversion on Immune Checkpoint Inhibitor Adverse Gastrointestinal Toxicities
Adames, S. M., Naz, S., Dai, J., Wang, Y., & Thomas, A. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134711
“However, this excessive immune activation can predispose patients to immune-related adverse events (irAEs) [3].”
Talab, T. J., Shafi, F. A. A., & Jasim, S. M. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.377 · Cited by 2
Pharmacogenetics and Pharmacogenomics in the Prediction of Cardiovascular Toxicity
Škrbić, R., Nežić, L., & Stojiljković, M. P. (2025) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-90598-8_28 · Cited by 1
Ran, H., Zhang, L., Wang, W., Xie, M., Wang, F., Chen, L., Pang, T., Chen, A., Zhu, J., & Cai, H. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf181 · Cited by 1
Lopci, E., Castello, A., Caracciolo, M., Mansi, L., & Al‐Ibraheem, A. (2026) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-032-21415-7_12
Nakano, Y., Miyamoto, S., Goto, K., Yukihiro, K., Tasaka, S., Nomura, N., Okazaki, M., Shikuma, H., Hatayama, T., Iwane, K., et al. (2026) · International Journal of Urology · doi:10.1111/iju.70579
“Because ICI therapy is associated with immune-related adverse events and substantial medical costs [5], postoperative decision-making should consider not only eligibility criteria but also the risk gradient within eligible populations, together with age, comorbidities, and functional status.”
Unlocking oncolytic virotherapy potential: leveraging bacteriophages to conquer immunosuppression
Boulfrad, B., & Larbi, A. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1957551
Metadata
- Authors
- Bajwa, R., Cheema, A., Khan, T., Amirpour, A., Paul, A., Chaughtai, S., Patel, S., Patel, T., Bramson, J., Gupta, V., Levitt, M., Asif, A., & Hossain, M. A.
- Affiliations
- Jersey Shore University Medical Center (US)
- Corresponding author
- Gupta, Varsha
- Venue
- Journal of Clinical Medicine Research
- Publisher
- Elmer Press, Inc.
- Published
- 2019
- Volume
- 11
- Issue
- 4
- Pages
- 225-236
- ISSN
- 1918-3003 (ISSN-L)
- 1918-3011
- PMC
- PMC6436564
- OpenAlex
- W2921474571
- Cited by
- 179
- References
- 123
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 16 · 2023: 13 · 2022: 21 · 2021: 40 · 2020: 53 · 2019: 8
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Journal of Clinical Medicine Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitors, immune-related adverse events, PD-1 inhibitors, CTLA-4 inhibitors, nivolumab, pembrolizumab, ipilimumab, colitis, hepatitis, adrenal insufficiency, hypothyroidism, type 1 diabetes, diabetic ketoacidosis, acute kidney injury, myocarditis, pancreatic dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.